Neumora Therapeutics (NASDAQ:NMRA) Insider Daljit Singh Aurora Sells 31,000 Shares

Neumora Therapeutics, Inc. (NASDAQ:NMRA) insider Daljit Singh Aurora sold 31,000 shares of Neumora Therapeutics stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $1.65, for a total value of $51,150.00. Following the completion of the transaction, the insider owned 48,750 shares of the company’s stock, valued at $80,437.50. The trade was a 38.87% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Daljit Singh Aurora also recently made the following trade(s):

• On Wednesday, August 19th, Daljit Singh Aurora sold 30,918 shares of Neumora Therapeutics stock. The shares were sold at an average price of $1.65, for a total transaction of $51,014.70.
• On Monday, August 17th, Daljit Singh Aurora sold 55,016 shares of Neumora Therapeutics stock. The shares were sold at an average price of $1.50, for a total transaction of $82,524.00.
• On Monday, August 17th, Daljit Singh Aurora sold 91,690 shares of Neumora Therapeutics stock. The stock was sold at an average price of $1.50, for a total transaction of $137,535.00.
• On Tuesday, August 18th, Daljit Singh Aurora sold 34,987 shares of Neumora Therapeutics stock. The stock was sold at an average price of $1.59, for a total transaction of $55,629.33.
• On Tuesday, August 18th, Daljit Singh Aurora sold 34,162 shares of Neumora Therapeutics stock. The shares were sold at an average price of $1.58, for a total transaction of $53,975.96.

Neumora Therapeutics Price Performance

Shares of NMRA remained flat at $1.64 during midday trading on Wednesday. 716,090 shares of the stock were exchanged, compared to its average volume of 699,708. The business has a fifty day moving average price of $1.61 and a two-hundred day moving average price of $2.11. Neumora Therapeutics, Inc. has a fifty-two week low of $0.83 and a fifty-two week high of $3.65. The company has a current ratio of 4.50, a quick ratio of 5.09 and a debt-to-equity ratio of 1.19.

Neumora Therapeutics (NASDAQ:NMRA) last posted its earnings results on Friday, August 14th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.01. Equities analysts forecast that Neumora Therapeutics, Inc. will post -0.85 EPS for the current fiscal year.

Institutional Trading of Neumora Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Invesco Ltd. raised its position in Neumora Therapeutics by 6.8% during the 2nd quarter. Invesco Ltd. now owns 132,038 shares of the company’s stock worth $97,000 after buying an additional 8,383 shares during the last quarter. Hsbc Holdings PLC acquired a new position in shares of Neumora Therapeutics during the fourth quarter worth about $27,000. HBK Sorce Advisory LLC purchased a new position in Neumora Therapeutics during the second quarter worth about $26,000. Virtu Financial LLC acquired a new stake in Neumora Therapeutics in the third quarter valued at about $31,000. Finally, Barclays PLC lifted its position in Neumora Therapeutics by 202.0% in the fourth quarter. Barclays PLC now owns 30,924 shares of the company’s stock valued at $55,000 after purchasing an additional 20,683 shares during the period. Hedge funds and other institutional investors own 47.65% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on NMRA shares. Needham & Company LLC decreased their target price on Neumora Therapeutics from $8.00 to $5.00 and set a “buy” rating for the company in a research note on Tuesday, June 16th. Wall Street Zen upgraded shares of Neumora Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday. Weiss Ratings cut shares of Neumora Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, August 14th. Royal Bank Of Canada reduced their price objective on shares of Neumora Therapeutics from $7.00 to $5.00 and set an “outperform” rating for the company in a research report on Monday, July 13th. Finally, HC Wainwright restated a “buy” rating on shares of Neumora Therapeutics in a report on Tuesday, July 28th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Neumora Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $6.57.

Key Neumora Therapeutics News

Here are the key news stories impacting Neumora Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS forecast to a loss of $0.89 from $1.29 and its FY2027 forecast to a loss of $0.68 from $1.25, indicating analysts expect substantially narrower losses over the next two years.
• Positive Sentiment: The firm also improved its quarterly outlook, forecasting a Q3 2026 loss of $0.20 per share versus $0.32 previously and a Q4 2026 loss of $0.16 versus $0.30 previously.
• Positive Sentiment: Longer-term estimates were upgraded sharply: FY2028’s projected loss narrowed to $0.52 from $1.10, FY2029 moved to projected profit of $0.20 from a $0.26 loss, and FY2030 profit expectations increased to $1.83 from $1.51 per share. These changes imply a faster potential transition to profitability.
• Positive Sentiment: HC Wainwright’s current estimates call for losses of $0.15, $0.16, $0.19 and $0.17 per share in the first four quarters of 2027, respectively, with full-year 2027 losses of $0.68. The firm’s continued Buy rating provides additional support for investor sentiment.
• Neutral Sentiment: Neumora remains unprofitable, with the broader current-year consensus at a loss of $0.93 per share. The company’s shares are trading well below their 200-day moving average and remain near the lower portion of their 12-month range, underscoring continued execution and financing risks despite the improved forecasts.

About Neumora Therapeutics

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.